AVXL · Anavex Life Sciences
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $1.48
Note written ·
Price against the kill line
36.9% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $1.48, on record since 11 November 2026. The shares are down 70.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $1.48, the highest close of the last 20 sessions, set on 15 October 2026, would show the shares leading the S&P 500 again. A Rett Phase 3 start date agreed with the FDA for pediatric patients would also show the case failing.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 June 2026, filed 28 August 2026
- Net cash, cash less debt ($M)
- 118
All filed numbers
What Anavex Life Sciences reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −13.0 | 7.8 |
| Diluted shares, change on a year (%) against the quarter to 30 June 2025 | +8.8 |
| Operating cash flow ($M) | −29.3 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 118 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 118 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 112 |
| Market value ($M) | Not available |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not available |
| Price to book value (×) | Not available |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): the share of shares outstanding is not available, 8.1 days of average trading to cover, −7.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
Anavex Life Sciences shares are more likely to lag the S&P 500 over the next three months. They closed at $1.06 on 11 November 2026, a 52-week closing low, after the board chair and two other directors resigned effective 28 October 2026. The FDA meeting on pediatric patients in the Rett syndrome Phase 3 trial, set for November, and the fiscal year-end report settle whether the slide ends.
The 3-month price change is −67.6%, from a close of $3.27 on 13 August 2026. The last close sits 85.4% below the 52-week intraday high of $7.25 set on 13 November 2025. The 50-day average of the adjusted close is $1.83 and the 200-day average is $2.93, both well above the price.
Closes since the resignations were $1.26 on 4 November 2026, $1.11 on 5 November 2026, $1.15 on 6 November 2026, $1.22 on 9 November 2026, $1.13 on 10 November 2026 and $1.06 on 11 November 2026. The clinical announcements of 15 October 2026 and 20 October 2026 did not lift the shares, and governance news has since dominated.
Bullish and bearish views on Anavex Life Sciences Corp.
The bull case on Anavex Life Sciences Corp. (AVXL), in brief: Clinical milestones were delivered. The bear case: three directors left over strategy.
Bull case
- Clinical milestones were delivered. The FDA cleared the Fragile X investigational new drug application on 15 October 2026, per RTTNews citing Anavex. On 20 October 2026 Anavex said it finished its drug-interaction and absorption studies with no serious adverse events in preliminary observations.
- Rett pediatric meeting is granted. Anavex's 20 October 2026 update says the FDA granted a November meeting on adding pediatric participants to the Rett Phase 3 protocol. The company has not announced the meeting date.
- Management is now permanent. Terrie Kellmeyer became President and CEO effective 1 November 2026 and joined the board, per the company announcement reported by Panabee on 3 November 2026. She had led the company as interim CEO since May 2026.
- Cash funds the plan. Anavex reported $118.3 million in cash and equivalents at 30 June 2026 and said management expected funding into mid-to-late fiscal 2028, per its fiscal third-quarter 2026 update.
- Shares trade far below prior levels. The close of $1.06 on 11 November 2026 compares with a 50-day average of $1.83. Good news from the FDA meeting or the year-end report would meet a very low starting price.
Bear case
- Three directors left over strategy. Chair Jiong Ma and directors Gautam Patel and Adrian Senderowicz resigned effective 28 October 2026, per the Form 8-K signed 2 November 2026. Ma said her views on strategic direction were "not fully aligned" with the board and management; the other two cited execution of the business plan.
- Two of the departures were recent nominees. Patel and Senderowicz had been named in the proxy contest with PVG Asset Management, per search coverage. They left five weeks after the 24 September 2026 vote, in which stockholders elected all six company nominees on 58.5% turnout.
- Good news did not lift the price. The shares closed at $1.06 on 11 November 2026, below the $1.11 close of 5 November 2026 and below every close listed since the resignations, after the October clinical announcements.
- The Alzheimer's path is unresolved. Anavex withdrew its European marketing application for blarcamesine after a negative opinion from the European Medicines Agency's human-medicines committee. The company has reported no agreed Alzheimer's Phase 3 design with the FDA.
- Legal overhang and sellable shares. A Glancy Prongay Wolke & Rotter notice dated 26 October 2026 invites investors who bought between 26 November 2025 and 28 August 2026 to seek lead-plaintiff status by 30 November 2026. The 24 September 2026 vote also fully vested all outstanding equity awards, per Anavex's Form 8-K.
Price setup
The close of $1.06 on 11 November 2026 is the lowest in the 52-week closing series and sits 85.4% below the 52-week intraday high of $7.25. The 50-day average of $1.83 and the 200-day average of $2.93 both slope above the price. The shares would have to rise about 40% to reach the highest close of the last 20 sessions, set on 15 October 2026.
The market has priced in a governance break and no price response to the October clinical news: the shares fell 67.6% over three months. The company has not confirmed the date of its fiscal year-end report; aggregators list about 24 November 2026. The 10-Q filed 28 August 2026 is the latest periodic report on EDGAR, and no SEC Form 4 insider transactions appear in recent filings.
Catalysts ahead
- November 2026 (date not announced): FDA meeting on adding pediatric participants to the Rett syndrome Phase 3 protocol. The outcome sets the size and timing of the Rett trial, the most advanced FDA-aligned program.
- 16 November 2026: Poster at the Clinical Trials on Alzheimer's Disease conference in Boston (runs to 19 November 2026). The first scientific presentation since the leadership change; content has not been disclosed.
- ~24 November 2026 (est.): Fiscal fourth-quarter and year-end results (aggregator date, unconfirmed). The first full financial report after the board vote, the equity-award acceleration and the director resignations; it shows cash and the cost of the vesting.
- 30 November 2026: Lead-plaintiff deadline in the securities class action, per a law-firm notice. Adds legal-overhang headlines; the case has no ruling yet.
What would change the view
A daily close above $1.48, the highest close of the last 20 sessions, set on 15 October 2026, would show the shares leading the S&P 500 again. A Rett Phase 3 start date agreed with the FDA for pediatric patients would also show the case failing.
What it trades with
Anavex trades on its own regulatory and governance news more than on sector moves. Its closest comparisons are small clinical-stage neurology companies that depend on a single drug and on FDA alignment. The 15 October 2026 and 20 October 2026 announcements moved the shares against the direction of the news, which points to company-specific supply and governance concerns rather than biotech market direction.
The evidence, claim by claim (7)
- Adjusted daily close was $1.06, a 52-week closing low; 52-week intraday high $7.25 on 13 November 2025; 3-month price change −67.6%. Split/dividend-adjusted daily bars · as of
- Board chair Jiong Ma and directors Gautam Patel and Adrian Senderowicz resigned effective 28 October 2026, each citing a mismatch with the board's and management's strategy; the audit committee was reconstituted on 1 November 2026. Anavex Form 8-K signed 2 November 2026 · as of
- Interim CEO Terrie Kellmeyer was named President and CEO effective 1 November 2026 and joins the board; the board is searching for an additional independent director. Anavex announcement via Panabee · as of
- The FDA cleared Anavex's investigational new drug application for blarcamesine in Fragile X syndrome; a Phase 2a trial of about 60 adult males is planned. RTTNews, citing Anavex announcement · as of
- Anavex finished clinical conduct of its 65-volunteer drug-interaction study and 8-volunteer absorption-and-excretion study, with no serious adverse events in preliminary observations; the FDA granted a November meeting on pediatric participants in the Rett Phase 3 protocol. Anavex corporate update via GlobeNewswire · as of
- Cash and cash equivalents were $118.3 million at fiscal third-quarter end; management expected funding into mid-to-late fiscal 2028. Anavex fiscal Q3 2026 business update · as of
- Stockholders elected all six company director nominees at the contested meeting; turnout was 58.5% of outstanding shares. Anavex Form 8-K, as summarised by Panabee · as of
Sources
- ANAVEX LIFE SCIENCES CORP. - Form 8-K - FY2026 · sec.gov ·
- Anavex Names Interim Chief Terrie Kellmeyer as Permanent CEO · panabee.com ·
- Kalkine Media
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…
BHVN
Biohaven
Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US…